Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- QURE
- Price
- 8.93
- Stock movement up
- +0.36 (4.20%)
- Company name
- Uniqure NV
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 435.28M
- Ent value
- 773.63M
- Price/Sales
- 15.23
- Price/Book
- 7.80
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 22.59%
- 1 year return
- 77.89%
- 3 year return
- -22.60%
- 5 year return
- -29.28%
- 10 year return
- -12.42%
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
uniQure's stock rises on Huntington's therapy progress and strong gene therapy pipeline. Learn about QURE stock's cost-cutting measures and analyst support.
February 26, 2025
iO Charts is a Seeking Alpha partner
DIVIDENDS
QURE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 15.23 |
| Price to Book | 7.80 |
| EV to Sales | 27.06 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 48.74M |
| EPS (TTM) | -4.92 |
| FCF per share (TTM) | -3.79 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 28.59M |
| Gross profit (TTM) | -3.25M |
| Operating income (TTM) | -204.74M |
| Net income (TTM) | -239.50M |
| EPS (TTM) | -4.92 |
| EPS (1y forward) | -3.12 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -11.39% |
| Operating margin (TTM) | -716.18% |
| Profit margin (TTM) | -837.80% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 251.63M |
| Net receivables | 5.32M |
| Total current assets | 464.14M |
| Goodwill | 24.08M |
| Intangible assets | 76.61M |
| Property, plant and equipment | 71.20M |
| Total assets | 645.81M |
| Accounts payable | 5.44M |
| Short/Current long term debt | 67.60M |
| Total current liabilities | 71.27M |
| Total liabilities | 589.99M |
| Shareholder's equity | 55.82M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -179.05M |
| Capital expenditures (TTM) | 5.40M |
| Free cash flow (TTM) | -184.45M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -429.05% |
| Return on Assets | -37.09% |
| Return on Invested Capital | -207.31% |
| Cash Return on Invested Capital | -159.66% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.60 |
| Daily high | 8.94 |
| Daily low | 8.42 |
| Daily Volume | 857K |
| All-time high | 82.19 |
| 1y analyst estimate | 29.64 |
| Beta | 0.90 |
| EPS (TTM) | -4.92 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 18 Jun 2025 |
Downside potential
Loading...
Downside potential data
| QURE | S&P500 | |
| Current price drop from All-time high | -89.13% | -12.89% |
| Highest price drop | -95.40% | -56.47% |
| Date of highest drop | 8 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -55.00% | -11.07% |
| Avg time to new high | 57 days | 12 days |
| Max time to new high | 1461 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
435.28M
Marketcap category
Small-cap
Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Employees
480
Website
Investor relations
-
SEC filings
CEO
Matthew C. Kapusta
Country
USA
City
Amsterdam
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page